2019 Novel Coronavirus Pneumonia
Conditions
Brief summary
the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of Xiyanping injection in patients with 2019-nCoV pneumonia.
Interventions
Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,
DRUGLopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride
Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride
Sponsors
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Laboratory examination (RT-PCR) confirms the infection 2019-nCoV, which meets the diagnostic criteria for pneumonia (common type) in the New Coronavirus Infection Pneumonia Diagnosis and Treatment Program (Trial Version 6); 2. The patient has a complete hospitalization record that can be used for research.
Exclusion criteria
\- Subjects who meet any of the following criteria cannot be enrolled: 1. Suffering from diseases that need to be distinguished from pneumonia infected with new coronavirus, such as tuberculosis, bacterial or viral pneumonia other than new coronavirus pneumonia, hospital-acquired pneumonia, and other pathogenic microorganisms pneumonia; 2. People with basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory tract malformations, abnormal lung development, aspiration pneumonia, and lung malignant tumors; 3. According to the judgment of the investigator, the previous or current disease may affect the patient's participation in the trial or the outcome of the study, including: malignant disease, autoimmune disease, liver and kidney disease, blood disease, neurological disease, and endocrine Disease; presently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or blood system, or splenectomy, organ transplantation, etc; 4. Pneumonia diagnosed with severe, critically re-associated coronavirus infection or requiring mechanical ventilation or systemic anti-hormonal therapy; 5. Used Chinese patent medicines with similar efficacy as Xiyanping injection during the treatment. 6. The investigator judges that the relevant test or data is missing during the treatment process, which affects the research evaluation or analyst.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical recovery time | Up to Day 14 | From the beginning of study drug use to fever, respiratory rate, blood oxygen saturation to normal and cough relief, and maintained for at least 72 hours or more, calculated in hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete fever time | Up to Day 14 | From the beginning of research drug use to body temperature \<37.3 ℃ (underarm) or mouth temperature ≤37.5 ° C, or anal or ear temperature ≤37.8 ° C, and maintained for 24h or more |
| Cough relief time | Up to Day 14 | Cough score day + night from the beginning of study medication to cough ≤ 1 point, and maintained for 24 hours and above |
| Virus negative time | Up to Day 14 | From the beginning of the study drug to two consecutive times (sampling interval of at least 1 day) |
| Incidence of severe or critical neocoronavirus pneumonia | Up to Day 14 | Defined as the proportion of subjects exacerbated during treatment and meeting the diagnostic criteria for severe or critical neocoronavirus pneumonia |
Contacts
Primary ContactHongzhou Lu, Master
Outcome results
None listed